Source-grounded facts extracted from INCYTE CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INCYTE CORP shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-08 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. For Against Abstain 173,072,501 12,457,655 116,713”
INCYTE CORP shareholders approved Advisory vote on executive compensation at the 2026-06-08 meeting.
“The compensation of the Company’s named executive officers was approved, on a non-binding advisory basis. For Against Abstain Broker Non-Votes 145,851,784 28,078,013 290,891 11,426,181”
INCYTE CORP shareholders approved Election of Directors at the 2026-06-08 meeting.
“The following directors were elected: For Against Abstain Broker Non-Votes Julian C. Baker 140,340,036 33,157,541 723,111 11,426,181”
INCYTE CORP reported first quarter of 2026 results: revenue $1.27 billion.
“furnished as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales”
Barry P. Flannelly retired as Executive Vice President, General Manager, North America at INCYTE CORP.
“On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor.”
INCYTE CORP entered into Purchase Agreement with Baker Entities (including Julian C. Baker, Felix J. Baker, and affiliates) valued at approximately $328.0 million (effective 2024-05-12).
“On May 12, 2024, Incyte Corporation (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with Julian C. Baker, a member of the Company’s board of directors, Felix J. Baker, and entities affiliated with Julian C. and Felix J. Baker, including funds advised by Baker Bros. Advisors LP (collectively, the “Baker Entities”).”
INCYTE CORP reported first fiscal quarter ended March 31, 2024 results: revenue Total revenues of $881 million in the first quarter (Q1'24). Guidance reaffirmed.
“Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million”
INCYTE CORP updated its fourth fiscal quarter and year ended December 31, 2023 guidance (initiated).
“On February 13, 2024, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2023.”
INCYTE CORP reported third fiscal quarter ended September 30, 2023 results: revenue $919 million. Guidance reaffirmed.
“Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $919 million in the third quarter (Q3'23)”
Maria E. Pasquale retired as Executive Vice President, General Counsel and Corporate Secretary at INCYTE CORP.
“On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023.”
INCYTE CORP reported second fiscal quarter ended June 30, 2023 results: revenue Total net product revenues of $827 million in the second quarter (Q2'23). Guidance raised.
“Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023”
INCYTE CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2023 at the 2023-06-14 meeting.
“6. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified. For Against Abstain 194,500,211 10,832,543 211,508”
INCYTE CORP shareholders approved Amendment to 1997 Employee Stock Purchase Plan at the 2023-06-14 meeting.
“5. The amendment to the Company’s 1997 Employee Stock Purchase Plan was approved. For Against Abstain Broker Non-Votes 191,553,726 1,633,296 39,202 12,318,038”
INCYTE CORP shareholders approved Amendment to Amended and Restated 2010 Stock Incentive Plan at the 2023-06-14 meeting.
“4. The amendment to the Company’s Amended and Restated 2010 Stock Incentive Plan was approved. For Against Abstain Broker Non-Votes 171,175,816 21,861,826 188,582 12,318,038”
INCYTE CORP shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-14 meeting.
“3. The stockholders recommended, on a non-binding advisory basis, that future non-binding advisory stockholder votes on the compensation of the Company’s named executive officers should occur every year. Every Year Every 2 Years Every 3 Years Abstain 191,089,985 42,182 1,896,908 197,149”
INCYTE CORP shareholders approved Advisory vote on executive compensation at the 2023-06-14 meeting.
“2. The compensation of the Company’s named executive officers was approved, on a non-binding advisory basis. For Against Abstain Broker Non-Votes 169,320,952 23,663,412 241,860 12,318,038”
INCYTE CORP shareholders approved Election of Directors at the 2023-06-14 meeting.
“The following actions were taken at the Annual Meeting of Stockholders of Incyte Corporation (the “Company”) held on June 14, 2023: 1. The following Directors were elected: For Against Abstain Broker Non- Votes Julian C. Baker 178,216,792 14,844,339 165,093 12,318,038”
INCYTE CORP reported first fiscal quarter ended March 31, 2023 results: revenue $693 million. Guidance raised.
“FOR IMMEDIATE RELEASE Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $693 million in Q1'23 (+14% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023”
INCYTE CORP reported third fiscal quarter ended September 30, 2022 results: revenue $713 million. Guidance raised.
“Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura TM (ruxolitinib) cream net product revenues – Jakafi net product rev enues of $620 million in Q3’22 (+13% Y/Y); raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion”
Susanne Schaffert was elected as Director at INCYTE CORP.
“Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company.”
Wendy L. Dixon departed as Director at INCYTE CORP.
“On April 18, 2022, Wendy L. Dixon notified Incyte Corporation (the “Company”) that she will be retiring from the Company’s Board of Directors, effective at the time of the Company’s 2022 Annual Meeting of Stockholders.”
Thomas Tray was appointed as Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer) at INCYTE CORP.
“Effective March 11, 2022, the board of directors of the Company appointed Thomas Tray, age 44, as the Company’s Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer).”
Paul Trower retired as Division Vice President, Finance and Principal Accounting Officer at INCYTE CORP.
“On January 10, 2022, Paul Trower notified Incyte Corporation (the “Company”) of his intention to retire as Division Vice President, Finance and Principal Accounting Officer of the Company effective March 11, 2022.”
Otis W. Brawley, M.D. was elected as member of the Board of Directors at INCYTE CORP.
“Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.